There are no discussions yet.

  • Disease Description

    Basal cell carcinoma's (BCC) are abnormal, uncontrolled growths or lesions that arise in the skin’s basal cells. Basal cells are cells which line the outermost layer of the skin. BCCs often have the appearance of open sores, red patches, pink growths, shiny bumps, or scars. They are usually caused by a combination of cumulative UV light exposure and intense, occasional UV light exposure. BCC’s can be highly disfiguring if allowed to grow, but almost never spreads (metastasizes) beyond the original tumor site to become a life threatening disease. [1]


    Prevalence


    Estimates of the incidence of BCC are imprecise since there is no cancer registry that collects data on BCC. The American Cancer society estimates that more than two million nonmelanoma skin cancers were treated in the United States in 2006, of which the majority would have been BCC [2]


    Current Treatment Options


    For superficial low-risk Basal Cell Carcinoma lesions treatment options include surgical excision, or topical treatment with topical 5-fluorouracil or imiquimod.[3]


    Evidence for and the Proposed Mechanism for Cannabinoid Threapies


    Accumulating recent evidence implicates the endocannabinoid system in the regulation of growth of skin cells. Casanova et al. have demonstrated that various human skin tumors (e.g. basal cell carcinoma, squamous cell carcinoma) express cannabinoid receptors both CB1 and CB2. Local administration of synthetic CB1 and CB2 agonists induced growth inhibition of malignant skin tumors in mice. This growth inhibition was accompanied by enhanced intra-tumor cell death and impaired tumor vascularization (altered blood vessel morphology, decreased expression of pro-angiogenic factors such as VEGF, placental growth factor and angiopoietin 2) [4]


    1. Skin Cancer Foundation. www.skincancer.org/


    2. American Cancer Society Cancer Facts and Figures 2010.


    3. UpToDate Online resources. Uptodate.com


    4. Pacher, P. et al. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci. Aug 2009; 30(8): 411–420.



    Loading content, please wait.
  • Category
    Critical Ailments
  • Created
    Thursday, 16 March 2017
  • Group admin
    CBIS

American States University

*** Warning this document contains graphic images.

Click the Below Image to Review our Cancer Drug Comparables

EBYH CSi EDP Drug Partner


1st HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.

Frontiers_1.JPG


2nd HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.

 Frontiers_2.JPG

*** PLUS

(3) other Cannabis Science
REAL WORLD Successes:

Stage 4 Breast Cancer

WhatsApp_Image_2022-05-21_at_9.37.37_AM_3.jpg
Skin Cancer 

WhatsApp_Image_2022-05-21_at_9.37.38_AM.jpeg
Karposis Sarcoma

WhatsApp_Image_2022-05-21_at_9.37.38_AM_1.jpeg

 
1mmStrongKC_Join_Now_Side_Bar.jpg1mmCover_Member2_Size.JPG

 

 CSi-Legacy_Drug_Update_SideBar.jpg

Drug Valuation Image3

Harvard GHC Award RCD 2018

 

The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.

Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.

We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.

 

Click here to review the Report:

Frontiers Capture
1mmStrong July 8 Court UPDATE Brochure Image

Sac Court Capture

Case No. 2:17-CV-02271-KJM-JDP



Inspire, Dream, Change

YOUR DIGITAL ERA Personal & Business Access Learning HUB
 


Observational Studies

PART

CSi-VIP & CBIS-Shareholder Legacy

1mmCover2.JPG

 Click the ABOVE Image to Review our 1-Million Strong FC, Media Kit

*** Warning this document contains exciting images. 

   Feb_2025.jpg

Pease Click the Calendar image to book your time to speak with Mr. Dabney about "Your Final CSi-VIP Shareholder Legacy". 

1mm_Member_Side_Bar_342x900Dec_12_2024.JPG

Click the above Image to become one of the First 1-Million Strong Killing Cancers, Fight Club Members to help 'Make that Change' Join in  Now!  *** Warning this Membership contains Exciting Results.

PS ...
ALL of our CSi-VIP's and those who Donated through the ASU/CSi-EDP GO-Fund-Me Promotion you do not need to purchase anything, you are ALREADY included in the "First" 1-Million Membership Club, CONGRATULATIONS !!!

 


Cannabis Science CEO, Presents …

The FINAL “CBIS GIFT Shares” Issuances!

DECEMBER 2024, Cheers! & HAPPY HOLIDAYS !!!

ALL GIFT Shares 1, 2, & 3 being ISSUED !!!

 LAST Steps:

Please confirm Yours NOW !!!

1. CONFIRM Correct Total Share Amount(s)

2. CONFIRM Correct Name(s) on CERTIFICATE

3. CONFIRM Correct Mailing Address

ASU/CSi-EDP-ECO-System
At it's FINEST !!! 

WHICH ONE ARE YOU ??

Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???

We can make this HAPPEN way FASTER Working as a TEAM !!!

WHAT Matters is how much you CARE about KILLING CANCERS ...

This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.



2025 Audit considerations NASDAQ.

Cannabis Science Inc.
Share Structure 2025

Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.

Common Stock:
Authorized:
5,000,000,000

Issued:
2,839,095,296

Fully Diluted:

4,510,547,648

Class A Common Stock
Authorized:
100,000,000

Issued:
0

Class B Common Stock
Authorized:
1,500,000,000

Issued:
0

Preferred Stock
Authorized:
1,000,000

Issued:
1,000,000

 


Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.

You already know our Extensive LIST of GROUNDBREAKING Products.

1-Million STRONG TV Coverage, HARVARD Award Success.

TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE




*** APPLY for FREE in CONFIDENCE and Success.

Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.

EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!

 

Activity Stream

What happened to my CBIS stock I owned years back
Thank you

What happened to my CBIS STOCK from7 YEARS AGO